A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://www.ncbi.nlm.nih.gov/pubmed/22198412
http://dx.doi.org/10.1007/s10549-011-1918-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://www.ncbi.nlm.nih.gov/pubmed/22198412
http://dx.doi.org/10.1007/s10549-011-1918-z

Ejemplares similares